Investing.com – Mizuho raised its price target on Spyre Therapeutics shares (NASDAQ:SYRE) to $84 from $53 while maintaining an Outperform rating. The stock surged to $63.18, up from a previous close of $51.77, reflecting investor enthusiasm following the trial results. The biotech has delivered a remarkable 320% return over the past year.
The price target increase follows topline data released Monday from the SPY001 Part A induction trial. Mizuho noted that every efficacy measure, including within subgroups, indicated best-in-class induction efficacy.
The firm said the monotherapy profile is compelling, but the most significant aspect of the data is the potential for SPY001-based combinations and the clinical remission rates that could be observed. Analyst sentiment remains strong, with five analysts recently revising their earnings estimates upward, according to an InvestingPro tip. The platform notes the stock currently trades above its Fair Value, appearing on the most overvalued stocks list.
Mizuho stated that if SPY002 and SPY003 behave like class peers and the Part B combinations behave like VEGA-experience, then SPY120 and SPY130 are positioned to achieve unprecedented induction clinical remission rates.
The firm increased its probability of success in inflammatory bowel disease by 10 percentage points and raised the assumed market share in the anti-tumor necrosis factor-naive population.
In other recent news, Spyre Therapeutics has seen multiple analyst firms update their price targets following positive clinical trial data. Leerink Partners raised its price target for Spyre to $106, maintaining an Outperform rating, citing increased probabilities of success for SPY001 in treating ulcerative colitis and Crohn’s disease. Jefferies also increased its price target to $85, highlighting numerical improvements in trial data over an existing treatment, Entyvio. Similarly, BTIG raised its target to $98, noting clinical remission and endoscopic improvement rates for SPY001 in ulcerative colitis patients. Stifel reiterated a Buy rating with a $92 price target, emphasizing the trial’s clinical remission achievements compared to Entyvio. Additionally, Goldman Sachs maintained its Early-Stage Biotech rating, pointing to a significant reduction in Robart’s Histopathology Index score in Spyre’s Phase 2 trial results. These developments reflect growing optimism among analysts regarding Spyre’s ongoing clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Source:
www.investing.com
